A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-...

Full description

Bibliographic Details
Main Authors:	Matteo Bassetti, Paolo Pelosi, Chiara Robba, Antonio Vena, Daniele Roberto Giacobbe
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2020-05-01
Series:	Drugs in Context
Subjects:	compassionate coronavirus covid-19 off-label rct sars-cov-2
Online Access:	https://www.drugsincontext.com/a-brief-note-on-randomized-controlled-trials-and-compassionate-off-label-use-of-drugs-in-the-early-phases-of-the-covid-19-pandemic

id	doaj-ccefbb9690554761b2f933fef843dd74
record_format	Article
spelling	doaj-ccefbb9690554761b2f933fef843dd742020-11-25T03:10:44ZengBioExcel Publishing LtdDrugs in Context1740-43982020-05-0191210.7573/dic.2020-5-2A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemicMatteo BassettiPaolo PelosiChiara RobbaAntonio VenaDaniele Roberto GiacobbeRandomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.https://www.drugsincontext.com/a-brief-note-on-randomized-controlled-trials-and-compassionate-off-label-use-of-drugs-in-the-early-phases-of-the-covid-19-pandemiccompassionatecoronaviruscovid-19off-labelrctsars-cov-2
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Matteo Bassetti Paolo Pelosi Chiara Robba Antonio Vena Daniele Roberto Giacobbe
spellingShingle	Matteo Bassetti Paolo Pelosi Chiara Robba Antonio Vena Daniele Roberto Giacobbe A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic Drugs in Context compassionate coronavirus covid-19 off-label rct sars-cov-2
author_facet	Matteo Bassetti Paolo Pelosi Chiara Robba Antonio Vena Daniele Roberto Giacobbe
author_sort	Matteo Bassetti
title	A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic
title_short	A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic
title_full	A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic
title_fullStr	A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic
title_full_unstemmed	A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic
title_sort	brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the covid-19 pandemic
publisher	BioExcel Publishing Ltd
series	Drugs in Context
issn	1740-4398
publishDate	2020-05-01
description	Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.
topic	compassionate coronavirus covid-19 off-label rct sars-cov-2
url	https://www.drugsincontext.com/a-brief-note-on-randomized-controlled-trials-and-compassionate-off-label-use-of-drugs-in-the-early-phases-of-the-covid-19-pandemic
work_keys_str_mv	AT matteobassetti abriefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT paolopelosi abriefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT chiararobba abriefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT antoniovena abriefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT danielerobertogiacobbe abriefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT matteobassetti briefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT paolopelosi briefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT chiararobba briefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT antoniovena briefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic AT danielerobertogiacobbe briefnoteonrandomizedcontrolledtrialsandcompassionateofflabeluseofdrugsintheearlyphasesofthecovid19pandemic
_version_	1724657658051428352

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Similar Items